Acute lymphoblastic leukemia, version 2.2015

Clinical practice guidelines in oncology

Joseph C. Alvarnas, Patrick A. Brown, Patricia Aoun, Karen Kuhn Ballen, Stefan K. Barta, Uma Borate, Michael W. Boyer, Patrick W. Burke, Ryan Cassaday, Januario E. Castro, Peter F. Coccia, Steven E. Coutre, Lloyd E. Damon, Daniel J. De Angelo, Dan Douer, Olga Frankfurt, John P. Greer, Robert A. Johnson, Hagop M. Kantarjian, Rebecca B. Klisovic & 10 others Gary Kupfer, Mark Litzow, Arthur Liu, Arati V. Rao, Bijal Shah, Geoffrey L. Uy, Eunice S. Wang, Andrew D. Zelenetz, Kristina Gregory, Courtney Smith

Research output: Contribution to journalReview article

37 Citations (Scopus)

Abstract

Treatment of acute lymphoblastic leukemia (ALL) continues to advance, as evidenced by the improved risk stratification of patients and development of newer treatment options. Identification of ALL subtypes based on immunophenotyping and cytogenetic and molecular markers has resulted in the inclusion of Philadelphia-like ALL and early T-cell precursor ALL as subtypes that affect prognosis. Identification of Ikaros mutations has also emerged as a prognostic factor. In addition to improved prognostication, treatment options for patients with ALL have expanded, particularly with regard to relapsed/refractory ALL. Continued development of second-generation tyrosine kinase inhibitors and the emergence of immunotherapy, including blinatumomab and chimeric antigen receptor T-cell therapy, have improved survival. Furthermore, incorporation of minimal residual disease (MRD) monitoring has shown insight into patient outcomes and may lead to treatment modification or alternative treatment strategies in select populations. This excerpt focuses on the sections of the ALL guidelines specific to clinical presentation and diagnosis, treatment of relapsed/refractory ALL, and incorporation of MRD monitoring. To view the most recent complete version of these guidelines, visit NCCN.org.

Original languageEnglish (US)
Pages (from-to)1240-1279
Number of pages40
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume13
Issue number10
StatePublished - Oct 1 2015
Externally publishedYes

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Practice Guidelines
Residual Neoplasm
Therapeutics
Guidelines
T-Lymphoid Precursor Cells
Immunophenotyping
Antigen Receptors
Cell- and Tissue-Based Therapy
Cytogenetics
Protein-Tyrosine Kinases
Immunotherapy
Mutation
Survival
Population

ASJC Scopus subject areas

  • Oncology

Cite this

Alvarnas, J. C., Brown, P. A., Aoun, P., Ballen, K. K., Barta, S. K., Borate, U., ... Smith, C. (2015). Acute lymphoblastic leukemia, version 2.2015: Clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network, 13(10), 1240-1279.

Acute lymphoblastic leukemia, version 2.2015 : Clinical practice guidelines in oncology. / Alvarnas, Joseph C.; Brown, Patrick A.; Aoun, Patricia; Ballen, Karen Kuhn; Barta, Stefan K.; Borate, Uma; Boyer, Michael W.; Burke, Patrick W.; Cassaday, Ryan; Castro, Januario E.; Coccia, Peter F.; Coutre, Steven E.; Damon, Lloyd E.; De Angelo, Daniel J.; Douer, Dan; Frankfurt, Olga; Greer, John P.; Johnson, Robert A.; Kantarjian, Hagop M.; Klisovic, Rebecca B.; Kupfer, Gary; Litzow, Mark; Liu, Arthur; Rao, Arati V.; Shah, Bijal; Uy, Geoffrey L.; Wang, Eunice S.; Zelenetz, Andrew D.; Gregory, Kristina; Smith, Courtney.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 13, No. 10, 01.10.2015, p. 1240-1279.

Research output: Contribution to journalReview article

Alvarnas, JC, Brown, PA, Aoun, P, Ballen, KK, Barta, SK, Borate, U, Boyer, MW, Burke, PW, Cassaday, R, Castro, JE, Coccia, PF, Coutre, SE, Damon, LE, De Angelo, DJ, Douer, D, Frankfurt, O, Greer, JP, Johnson, RA, Kantarjian, HM, Klisovic, RB, Kupfer, G, Litzow, M, Liu, A, Rao, AV, Shah, B, Uy, GL, Wang, ES, Zelenetz, AD, Gregory, K & Smith, C 2015, 'Acute lymphoblastic leukemia, version 2.2015: Clinical practice guidelines in oncology', JNCCN Journal of the National Comprehensive Cancer Network, vol. 13, no. 10, pp. 1240-1279.
Alvarnas, Joseph C. ; Brown, Patrick A. ; Aoun, Patricia ; Ballen, Karen Kuhn ; Barta, Stefan K. ; Borate, Uma ; Boyer, Michael W. ; Burke, Patrick W. ; Cassaday, Ryan ; Castro, Januario E. ; Coccia, Peter F. ; Coutre, Steven E. ; Damon, Lloyd E. ; De Angelo, Daniel J. ; Douer, Dan ; Frankfurt, Olga ; Greer, John P. ; Johnson, Robert A. ; Kantarjian, Hagop M. ; Klisovic, Rebecca B. ; Kupfer, Gary ; Litzow, Mark ; Liu, Arthur ; Rao, Arati V. ; Shah, Bijal ; Uy, Geoffrey L. ; Wang, Eunice S. ; Zelenetz, Andrew D. ; Gregory, Kristina ; Smith, Courtney. / Acute lymphoblastic leukemia, version 2.2015 : Clinical practice guidelines in oncology. In: JNCCN Journal of the National Comprehensive Cancer Network. 2015 ; Vol. 13, No. 10. pp. 1240-1279.
@article{7bfc3ed1547a48608a122fe5b30861c7,
title = "Acute lymphoblastic leukemia, version 2.2015: Clinical practice guidelines in oncology",
abstract = "Treatment of acute lymphoblastic leukemia (ALL) continues to advance, as evidenced by the improved risk stratification of patients and development of newer treatment options. Identification of ALL subtypes based on immunophenotyping and cytogenetic and molecular markers has resulted in the inclusion of Philadelphia-like ALL and early T-cell precursor ALL as subtypes that affect prognosis. Identification of Ikaros mutations has also emerged as a prognostic factor. In addition to improved prognostication, treatment options for patients with ALL have expanded, particularly with regard to relapsed/refractory ALL. Continued development of second-generation tyrosine kinase inhibitors and the emergence of immunotherapy, including blinatumomab and chimeric antigen receptor T-cell therapy, have improved survival. Furthermore, incorporation of minimal residual disease (MRD) monitoring has shown insight into patient outcomes and may lead to treatment modification or alternative treatment strategies in select populations. This excerpt focuses on the sections of the ALL guidelines specific to clinical presentation and diagnosis, treatment of relapsed/refractory ALL, and incorporation of MRD monitoring. To view the most recent complete version of these guidelines, visit NCCN.org.",
author = "Alvarnas, {Joseph C.} and Brown, {Patrick A.} and Patricia Aoun and Ballen, {Karen Kuhn} and Barta, {Stefan K.} and Uma Borate and Boyer, {Michael W.} and Burke, {Patrick W.} and Ryan Cassaday and Castro, {Januario E.} and Coccia, {Peter F.} and Coutre, {Steven E.} and Damon, {Lloyd E.} and {De Angelo}, {Daniel J.} and Dan Douer and Olga Frankfurt and Greer, {John P.} and Johnson, {Robert A.} and Kantarjian, {Hagop M.} and Klisovic, {Rebecca B.} and Gary Kupfer and Mark Litzow and Arthur Liu and Rao, {Arati V.} and Bijal Shah and Uy, {Geoffrey L.} and Wang, {Eunice S.} and Zelenetz, {Andrew D.} and Kristina Gregory and Courtney Smith",
year = "2015",
month = "10",
day = "1",
language = "English (US)",
volume = "13",
pages = "1240--1279",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "10",

}

TY - JOUR

T1 - Acute lymphoblastic leukemia, version 2.2015

T2 - Clinical practice guidelines in oncology

AU - Alvarnas, Joseph C.

AU - Brown, Patrick A.

AU - Aoun, Patricia

AU - Ballen, Karen Kuhn

AU - Barta, Stefan K.

AU - Borate, Uma

AU - Boyer, Michael W.

AU - Burke, Patrick W.

AU - Cassaday, Ryan

AU - Castro, Januario E.

AU - Coccia, Peter F.

AU - Coutre, Steven E.

AU - Damon, Lloyd E.

AU - De Angelo, Daniel J.

AU - Douer, Dan

AU - Frankfurt, Olga

AU - Greer, John P.

AU - Johnson, Robert A.

AU - Kantarjian, Hagop M.

AU - Klisovic, Rebecca B.

AU - Kupfer, Gary

AU - Litzow, Mark

AU - Liu, Arthur

AU - Rao, Arati V.

AU - Shah, Bijal

AU - Uy, Geoffrey L.

AU - Wang, Eunice S.

AU - Zelenetz, Andrew D.

AU - Gregory, Kristina

AU - Smith, Courtney

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Treatment of acute lymphoblastic leukemia (ALL) continues to advance, as evidenced by the improved risk stratification of patients and development of newer treatment options. Identification of ALL subtypes based on immunophenotyping and cytogenetic and molecular markers has resulted in the inclusion of Philadelphia-like ALL and early T-cell precursor ALL as subtypes that affect prognosis. Identification of Ikaros mutations has also emerged as a prognostic factor. In addition to improved prognostication, treatment options for patients with ALL have expanded, particularly with regard to relapsed/refractory ALL. Continued development of second-generation tyrosine kinase inhibitors and the emergence of immunotherapy, including blinatumomab and chimeric antigen receptor T-cell therapy, have improved survival. Furthermore, incorporation of minimal residual disease (MRD) monitoring has shown insight into patient outcomes and may lead to treatment modification or alternative treatment strategies in select populations. This excerpt focuses on the sections of the ALL guidelines specific to clinical presentation and diagnosis, treatment of relapsed/refractory ALL, and incorporation of MRD monitoring. To view the most recent complete version of these guidelines, visit NCCN.org.

AB - Treatment of acute lymphoblastic leukemia (ALL) continues to advance, as evidenced by the improved risk stratification of patients and development of newer treatment options. Identification of ALL subtypes based on immunophenotyping and cytogenetic and molecular markers has resulted in the inclusion of Philadelphia-like ALL and early T-cell precursor ALL as subtypes that affect prognosis. Identification of Ikaros mutations has also emerged as a prognostic factor. In addition to improved prognostication, treatment options for patients with ALL have expanded, particularly with regard to relapsed/refractory ALL. Continued development of second-generation tyrosine kinase inhibitors and the emergence of immunotherapy, including blinatumomab and chimeric antigen receptor T-cell therapy, have improved survival. Furthermore, incorporation of minimal residual disease (MRD) monitoring has shown insight into patient outcomes and may lead to treatment modification or alternative treatment strategies in select populations. This excerpt focuses on the sections of the ALL guidelines specific to clinical presentation and diagnosis, treatment of relapsed/refractory ALL, and incorporation of MRD monitoring. To view the most recent complete version of these guidelines, visit NCCN.org.

UR - http://www.scopus.com/inward/record.url?scp=84944747962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944747962&partnerID=8YFLogxK

M3 - Review article

VL - 13

SP - 1240

EP - 1279

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 10

ER -